Latanoprostene Bunod Patent Expiration
Latanoprostene Bunod is Used for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It was first introduced by Bausch And Lomb Inc
Latanoprostene Bunod Patents
Given below is the list of patents protecting Latanoprostene Bunod, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vyzulta | US8058467 | Prostaglandin derivatives | Feb 21, 2029 | Bausch And Lomb |
| Vyzulta | US7273946 | Prostaglandin derivatives | Oct 03, 2025 | Bausch And Lomb |
| Vyzulta | US7629345 | Prostaglandin derivatives |
Jan 05, 2025
(Expired) | Bausch And Lomb |
| Vyzulta | US7910767 | Prostaglandin derivatives |
Jan 05, 2025
(Expired) | Bausch And Lomb |
| Vyzulta | US6211233 | Prostaglandin pharmaceutical compositions |
Jun 17, 2018
(Expired) | Bausch And Lomb |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Latanoprostene Bunod's patents.
Latest Legal Activities on Latanoprostene Bunod's Patents
Given below is the list recent legal activities going on the following patents of Latanoprostene Bunod.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Certificate Critical | 18 Mar, 2024 | US8058467 |
| Withdrawal of Application for PTE Critical | 18 Mar, 2024 | US7273946 |
| Withdrawal of Application for PTE Critical | 18 Mar, 2024 | US7629345 |
| Notice of Final Determination -Election Required | 13 Feb, 2024 | US7273946 |
| Notice of Final Determination -Election Required | 13 Feb, 2024 | US7629345 |
| Notice of Final Determination -Election Required | 13 Feb, 2024 | US8058467 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 02 Feb, 2024 | US7629345 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 02 Feb, 2024 | US7273946 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 02 Feb, 2024 | US8058467 |
| Requirement for information sent under 37 CFR 1.750 | 26 Jan, 2024 | US8058467 |
Latanoprostene Bunod's Family Patents
Explore Our Curated Drug Screens
Latanoprostene Bunod Generic API Manufacturers
Only one generic application has been filed for Latanoprostene Bunod.
Given below is the list of companies who have filed for Latanoprostene Bunod generic, along with the locations of their manufacturing plants worldwide.
1. GLAND
Gland Pharma Ltd has filed for 1 generic for Latanoprostene Bunod. Given below are the details of the strengths of this generic introduced by Gland.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.024% | solution/drops | Prescription | OPHTHALMIC | AB | Apr 29, 2025 |
Manufacturing Plant Locations New
Gland's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Gland as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||